|
1) 日本呼吸器学会COPDガイドライン作成委員会. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン. 東京: メディカルレビュー社; 1999
|
|
|
|
|
2) National Institute of Health, National Heart, Lung, and Blood Institute. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2001
|
|
|
|
|
|
3) 日本呼吸器学会COPDガイドライン作成委員会. COPD診断と治療のためのガイドライン. 東京: メディカルレビュー社; 2004
|
|
|
|
|
|
4) National Institute of Health, National Heart, Lung, and Blood Institute. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2006
|
|
|
|
|
|
5) Ciba Guest Symposium Report. Terminology, definition and classification of chronic pulmonary emphysema and related conditions. Thorax. 1964; 14: 286-99
|
|
|
|
|
|
6) Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet. 1965; 1: 775-9
|
|
|
|
|
|
7) American Thoracic Society. Chronic bronchitis, asthma, and pulmonary emphysema. A statement by the committee on diagnostic standards for nontuberculous respiratory disease. Am Rev Respir Dis. 1962; 85: 762-8
|
|
|
|
|
|
8) American Thoracic Society. A statement of the committee on therapy; Chronic obstructive lung disease. Am Rev Respir Dis. 1965; 92: 513-8
|
|
|
|
|
9) Burrows B, Fletcher CM, Heard BE, et al. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet. 1966; 1: 830-5
|
|
|
|
|
|
10) Filley GF, Beckwitt HJ, Reeves JT, et al. Chronic obstructive bronchopulmonary disease. II. Oxygen transport in two clinical types. Am J Med. 1968; 44: 26-38
|
|
|
|
|
11) Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med. 1968; 278: 1355-60
|
|
|
|
|
|
12) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987; 136: 225-44
|
|
|
|
|
|
13) Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350: 2645-53
|
|
|
|
|
|
14) Makita H, Nasuhara Y, Betsuyaku T, et al. Characterization of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax. 2007; 62: 932-7
|
|
|
|
|
|
15) Hasegawa M, Nasuhara Y, Onodera Y, et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 173: 1309-15
|
|
|
|
|
|
16) 南方良章, 一ノ瀬正和. COPDの病態. In: 工藤翔二, 他編. Annual Review 呼吸器 2007. 東京: 中外医学社; 2007. p. 87-97
|
|
|
|
|
|
17) Fletcher CM, Peto R. The natural history of chronic airflow obstruction. BMJ. 1977; 1: 1645-8
|
|
|
|
|
|
18) Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease and health related quality of life. Ann Intern Med. 1997; 127: 1072-9
|
|
|
|
|
|
19) Friedman M, Serby C, Menjoge S, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest. 1999; 115: 635-41
|
|
|
|
|
|
20) Dewan N, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factor associated with poor treatment outcome. Chest. 2000; 117: 662-71
|
|
|
|
|
|
21) Anthonisen NR, Wright EC, Hodgkin JE. The IPPB Trial Group. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986; 133: 14-20
|
|
|
|
|
|
22) Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350: 1005-12
|
|
|
|
|
|
23) Agusti AGN, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003; 21: 347-60
|
|
|
|
|
|
24) Celli BR. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. Proc Am Thorac Soc. 2006; 3: 461-6
|
|
|
|
|
|
25) Braman SS. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129: 104S-15S
|
|
|
|
|
|
26) Fletcher CM, Pride NB. Definitions of emphysema, chronic bronchitis, asthma, and airflow obstruction: 25 years on from the Ciba symposium. Thorax. 1984; 39: 81-5
|
|
|
|
|
|
27) Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996; 153: 1530-5
|
|
|
|
|
|
28) Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003; 58: 659-64
|
|
|
|
|
|
29) Hizawa N, Makita H, Nasuhara Y, et al. β2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest. 2007. in press
|
|
|
|
|
|
30) National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med. 2001; 345: 1075-83
|
|
|
|
|